TWI602585B - 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法 - Google Patents

一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法 Download PDF

Info

Publication number
TWI602585B
TWI602585B TW103110986A TW103110986A TWI602585B TW I602585 B TWI602585 B TW I602585B TW 103110986 A TW103110986 A TW 103110986A TW 103110986 A TW103110986 A TW 103110986A TW I602585 B TWI602585 B TW I602585B
Authority
TW
Taiwan
Prior art keywords
gas
pharmaceutical composition
inhaled pharmaceutical
hydrogen
treating alzheimer
Prior art date
Application number
TW103110986A
Other languages
English (en)
Other versions
TW201536360A (zh
Inventor
林信湧
Original Assignee
林信湧
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 林信湧 filed Critical 林信湧
Priority to TW103110986A priority Critical patent/TWI602585B/zh
Priority to CN201410400001.5A priority patent/CN104940209A/zh
Priority to US14/664,483 priority patent/US9463157B2/en
Priority to JP2015060832A priority patent/JP2015183005A/ja
Priority to DE102015104362.9A priority patent/DE102015104362A1/de
Priority to KR1020150041674A priority patent/KR20150111327A/ko
Publication of TW201536360A publication Critical patent/TW201536360A/zh
Application granted granted Critical
Publication of TWI602585B publication Critical patent/TWI602585B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B1/00—Electrolytic production of inorganic compounds or non-metals
    • C25B1/01—Products
    • C25B1/02—Hydrogen or oxygen
    • C25B1/04—Hydrogen or oxygen by electrolysis of water
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B15/00—Operating or servicing cells
    • C25B15/08—Supplying or removing reactants or electrolytes; Regeneration of electrolytes
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B9/00—Cells or assemblies of cells; Constructional parts of cells; Assemblies of constructional parts, e.g. electrode-diaphragm assemblies; Process-related cell features
    • C25B9/17—Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8218—Gas operated
    • A61M2205/8231—Gas operated using electrochemical gas generating device for the driving gas
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis

Description

一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法
本發明係有關於一種吸入式醫藥組成物及其備製方法，特別是有關於一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法。
阿茲海默症(Alzheimer's disease,AD)主要是以認知功能衰退為主要的病徵，得到阿茲海默症的人會漸漸的喪失記憶並出現語言和情緒上的障礙。因此在疾病的治療與病人日常生活上的照顧需花費許多社會成本，同時病患家屬的生活亦會受到很大的影響。
因此，阿茲海默症之治療成為極重要的議題，目前美國食品藥物管制局(US Food and Drug Administration,FDA)核准用以治療阿茲海默症的藥物有兩類，一類是受體拮抗劑(N-Methyl-D-Aspartate,NMDA)代表藥物是美金剛胺鹽酸鹽(Memantine Hydrochloride)，另一類是膽鹼酶抑制劑(Cholinesterase Inhibitors)，包含有重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)與氫溴酸加蘭他敏(Galantamine Hydrobromide)。其中，由於乙醯膽鹼是一種神經傳導物質，透過這些藥物能夠阻斷膽鹼酶(Cholinesterase)的作用藉以抑制乙醯膽鹼(acetylcholine)的分解，同時亦可以增加腦中乙醯膽鹼(Acetylcholine)的含 量，進而改善病症以及延緩記憶退化。然而，這些藥物並不能治癒阿茲海默症，它們只能減輕阿茲海默症的症狀。此外，此些藥品均會對患者造成一些副作用，如噁心、頭痛、腹瀉、失眠、疼痛、幻覺或暈眩等。
如上所述，因此目前缺乏一種能兼具治療效果且降低對患者產生副作用之阿茲海默症之藥劑。
有鑒於此，本發明提供一種用於治療阿茲海默症之吸入式醫藥組成物，其包含一第一氣體及一霧化藥液。第一氣體包含一氫氣，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~96%之間。霧化藥液包含選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合。
根據本發明之一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物，第一氣體係藉由電解水所產生之一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。於一實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~66.66%之間。此外，本發明吸入式醫藥組成物另包含一第二氣體，用以降低吸入式醫藥組成物中氫氣之氣體體積濃度，其中第二氣體係為選自於由空氣、水蒸汽、鈍氣、氧氣及其組合所組成族群中的一種氣體。於另一實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度介於4.7%~66.66%之間。
根據本發明之另一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物，氫氣佔吸入式醫藥組成物之氣體體積濃度介於 60%~66.66%之間。此外，於另一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物，氫氣佔吸入式醫藥組成物之氣體體積濃度大於66.66%。
此外，本發明另提供一種用於治療阿茲海默症之吸入式醫藥組成物之製備方法，包含下列步驟：(S1)備製一第一氣體，第一氣體包含一氫氣；(S2)霧化一藥液以產生一霧化藥液，藥液包含選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合；以及(S3)混合第一氣體以及霧化藥液以產生該吸入式醫藥組成物，其中氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~96%之間。
根據本發明之一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物之製備方法，本發明方法之步驟(S1)係為電解水以產生第一氣體，第一氣體含一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。
根據本發明之另一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物之製備方法，本發明方法之步驟包含：(S21)備製一第一氣體，第一氣體包含一氫氣；(S22)霧化一藥液以產生一霧化藥液，藥液包含選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合；(S23)準備一第二氣體；以及 (S24)混合第一氣體、第二氣體以及霧化藥液以產生吸入式醫藥組成物，其中第二氣體用以降低吸入式醫藥組成物中該氫氣之氣體體積濃度。於此實施例中，本發明用於治療阿茲海默症之吸入式醫藥組成物中氫氣佔吸入式醫藥組成物之氣體體積濃度，可因第二氣體加入而降低吸入式醫藥組成物中該氫氣之氣體體積濃度。
此外，根據本發明之另一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物之製備方法，其中氫氣佔吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。於另一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物之製備方法，其中氫氣佔吸入式醫藥組成物之氣體體積濃度大於66.66%。
相較於習知技術，本發明提供一種用於治療阿茲海默症之吸入式醫藥組成物及其製備方法，本發明吸入式醫藥組成物除了可以提供患者直接吸入之服用便利性外，並可以藉由氫氣以去除患者體內之惡性自由基，並藉由霧化藥液以增加患者之藥物吸收療效。
S1~S3、S21~S24‧‧‧流程步驟
100‧‧‧電解裝置
200‧‧‧氣體混合系統
102‧‧‧電解槽
104‧‧‧電解水
106A、106B‧‧‧電極
108‧‧‧第一氣體
110‧‧‧第一氣體管路
210‧‧‧霧化/揮發氣體混合槽
212‧‧‧霧化藥液
214‧‧‧吸入式醫藥組成物
216‧‧‧震盪器
220‧‧‧藥液
第一圖係繪示本發明之用於治療阿茲海默症之吸入式醫藥組成物之製備方法於一具體實施例之方法流程圖。
第二圖係繪示本發明之用於治療阿茲海默症之吸入式醫藥組成物之製備方法於另一具體實施例之方法流程圖。
第三圖係繪示本發明之用於治療阿茲海默症之吸入式醫藥組成物之製備方法中步驟(S1)於一具體實施例之電解裝置示意圖。
第四圖係繪示本發明之用於治療阿茲海默症之吸入式醫藥 組成物之製備方法中步驟(S2)及(S3)於一具體實施例之氣體混合系統之示意圖。
為了讓本發明的優點，精神與特徵可以更容易且明確地了解，後續將以實施例並參照所附圖式進行詳述與討論。值得注意的是，這些實施例僅為本發明代表性的實施例，其中所舉例的特定方法、裝置、條件、材質等並非用以限定本發明或對應的實施例。
本發明提出一種用於治療阿茲海默症之吸入式醫藥組成物，其包含一第一氣體及一霧化藥液。第一氣體包含一氫氣，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~96%之間。霧化藥液包含選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合。
於本發明之實施例中，第一氣體更包含一氧氣，而第一氣體係藉由電解水所產生之一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。而霧化藥液則係藉由針對一藥液進行霧化或揮發所產生，其中藥液包含選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合，且上述藥物應用於阿茲海默症治療上已為本領域的技術人員所熟知，故在此不多加贅述。於本實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~66.66%之間。
本發明吸入式醫藥組成物另包含一第二氣體，第二氣體用以降低吸入式醫藥組成物中氫氣之氣體體積濃度，其中第二氣體係為選自於由空氣、水蒸汽、鈍氣、氧氣及其組合所組成族群中的一種氣體。於本實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度可介於4.7%~66.66%之間，惟不以此範圍為限。
於另一具體實施例中，本發明吸入式醫藥組成物可以藉由混合第一氣體以及霧化一體積為40c.c.之藥液所產生之霧化藥液所製備，而氫氣佔吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。於另一實施例中，也可以用氫氣瓶提供所需氫氣，並與霧化藥液進行混合，此時氫氣佔吸入式醫藥組成物之氣體體積濃度將可能會高於66.66%，例如67%~96%之間。於另一實施例中，也可直接蒐集電解水中所產生之氫氣(而非氫氧混合氣)直接與霧化藥液進行混合，此時氫氣佔吸入式醫藥組成物之氣體體積濃度將也會高於66.66%。
請參閱第一圖，係繪示本發明之用於治療阿茲海默症之吸入式醫藥組成物之製備方法於一具體實施例之方法流程圖。如圖所示，本發明吸入式醫藥組成物之製備方法包含下列步驟：(S1)備製一第一氣體，第一氣體包含有一氫氣；(S2)霧化一藥液以產生一霧化藥液，藥液包含有選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合；以及(S3)混合第一氣體以及霧化藥液以產生吸入式醫藥組成物，其中氫氣 佔吸入式醫藥組成物之氣體體積濃度介於2%~96%之間。
根據本發明之一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物之製備方法，本發明方法之步驟(S1)係為電解水以產生第一氣體，第一氣體含一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。於一實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~66.66%之間，惟不以此範圍為限。
請參閱第二圖，係繪示本發明之用於治療阿茲海默症之吸入式醫藥組成物之製備方法於另一具體實施例之方法流程圖。如圖所示，本發明吸入式醫藥組成物之另一製備方法，包含下列步驟：(S21)備製一第一氣體，第一氣體包含有一氫氣；(S22)霧化一藥液以產生一霧化藥液，藥液包含有選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合；以及(S23)準備一第二氣體；以及(S24)混合第一氣體、第二氣體以及霧化藥液以產生吸入式醫藥組成物。
根據本發明之一實施例提供一種用於治療阿茲海默症之吸入式醫藥組成物之製備方法，本發明方法之步驟(S21)係為電解水以產生第一氣體，第一氣體含一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。此外，本發明用於治療阿茲海默症之吸入式醫藥組成物中氫氣佔吸入式醫藥組成物之氣體體積濃度，可因第二氣體加入而降低吸入式醫藥組成物中該 氫氣之氣體體積濃度，於本實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度可介於4.7%~66.66%之間，惟不以此範圍為限。
當然，於另一實施例中，也可以用氫氣瓶提供所需氫氣，並與霧化藥液進行混合，此時氫氣佔吸入式醫藥組成物之氣體體積濃度將可能會高於66.66%，例如67%~96%之間。但因吸入氣體中氫氣體積濃度太高(如高於96%)可能使氧氣體積濃度太低而對人體產生缺氧之不良影響，因此此時需注意控制氫氣體積濃度不要高於96%，如介於67%~90%之間。於另一實施例中，也可直接蒐集電解水中所產生之氫氣(而非氫氧混合氣)直接與霧化藥液進行混合，此時氫氣佔吸入式醫藥組成物之氣體體積濃度將也會高於66.66%。
請參閱第三圖，係繪示本發明之用於治療阿茲海默症之吸入式醫藥組成物之製備方法中步驟(S1)於一具體實施例之電解裝置示意圖。於本實施例中，本發明能夠藉由電解水以產生含有氫氧混合氣體之第一氣體，其中電解裝置100包含一電解槽102、一電解水104、電極106A、106B以及一電源。
首先，電解槽102用以容納電解水104，其中電解水104主要成份為純水，惟不以此為限，於實際應用時，電解水能夠視需要以添加少量的電解質，如氫氧化鈉、碳酸鈣、氯化鈉等。再者，電解槽102中包含電極106A、106B，電極106A、106B分別為一陰極電極及一陽極電極，並耦接至一電源(未繪示於圖中)，藉以提供電解水所需之電能。於一具體實施例中，電極106A、106B能夠是固定的極性，如電極106A為陰極，電極106B為陽極，惟電極的極性不以固定為限。於另一具體實施例中，電極106A、 106B能夠是交替變換的極性，如在某一時間點，電極106A為陰極，電極106B為陽極；經過一預定時間後，在另一時間點，電極106A切換為陽極，電極106B切換為陰極，其後依此類推。
接著，電解槽102中的電解水104經過電極106A、106B通電後會開始電解，而在陰極(負極)產生氫氣，陽極(正極)產生氧氣，且釋出於電解槽102的上部，以形成一第一氣體108，其中第一氣體108由電解槽102的第一氣體管路110輸出，以作為後續的使用，惟不以此為限。於另一個實施例中，本發明亦能夠將陰極產生之氫氣與陽極產生之氧氣，個別以一氣體導管導引出電解槽102，之後再進行混合而產生第一氣體108。
由於電解水104經過電解後所產生的氫氣及氧氣之體積比約為2：1。於一具體實施例中，本發明能夠再添加第二氣體112，藉以降低吸入式醫藥組成物中該氫氣之氣體體積濃度，例如氫氣佔吸入式醫藥組成物之氣體體積濃度可以控制介於4.7%~66.66%之間，其中第二氣體係為選自於由空氣、水蒸汽、鈍氣、氧氣及其組合所組成族群中的一種氣體。
請參閱第四圖，係繪示本發明之用於治療阿茲海默症之吸入式醫藥組成物之製備方法中步驟(S2)及(S3)於一具體實施例之氣體混合系統之示意圖。本發明吸入式醫藥組成物之製備方法中步驟(S2)及(S3)可以藉由氣體混合系統200，藉以霧化藥液220並混合第一氣體108進而產生吸入式醫藥組成物214。
氣體混合系統200包含一霧化/揮發氣體混合槽210，霧化/揮發氣體混合槽210藉由第一氣體管路110與電解裝置100(如第三圖所示)耦接，以接收第一氣體108，並與霧化藥液212混合，以形成吸入式醫藥組成 物214。霧化/揮發氣體混合槽210更包括一震盪器216(例如超音波震盪器)，適於對霧化/揮發氣體混合槽210中藥液220進行霧化，以產生霧化藥液212。藥液220可以為重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合，且上述藥物應用於阿茲海默症治療上已為本領域的技術人員所熟知，故在此不多加贅述。
於另一具體實施例中，霧化/揮發氣體混合槽210中可容納之藥液約40~100c.c之範圍，預估以60分鐘內霧化完畢，故霧化藥液本身產氣量約0.67cc/min~1.67cc/min之間，而電解槽102控制每分鐘產氣量約2,000cc/min~3,000cc/min之間，其中如電解槽產氣之結果僅僅是氫氧混合氣(氫氣及氧氣之體積比約為2：1)，則氫氣佔吸入式醫藥組成物之氣體體積濃度介於66.61%~66.65%之間。但有時因電解槽電解之熱能，會蒸發電解水而使電解槽產氣之結果除氫氧混合氣外，還可能含有少量些許之水蒸氣，因此氫氣佔吸入式醫藥組成物之氣體體積濃度會低於66.61%，例如介於60%~66.61%之間，當然上述之少量些許水蒸氣可以藉由降溫而減少。本發明吸入式醫藥組成物之備製方法可以藉由混合氫氧混合氣以及霧化藥液所製備，一般而言氫氣佔吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。
由上述實施例可知，本發明吸入式醫藥組成物包含氫氣與霧化藥液，以提供患者(未繪示)吸入。人體因各種原因，(比如疾病、飲食、所處環境或生活習慣)引生的惡性自由基，亦稱有害自由基，可以與吸入的氫氣還原成部份的水，而排出體外。間接減少人體自由基的數量，達到酸 性體質還原至健康的鹼性體質，可以抗氧化進而也達到消除慢性疾病效果。另外，液態藥液經過霧化後形成1~5微米的藥水粒子，經由吸入的方式，而透過鼻黏膜或肺泡直接吸收，可以更有利於人體吸收，也就是說較少霧化藥液劑量即可達成原先一般口服或注射所需要藥劑量之治療效果，也因為使用少量霧化藥液劑量，也間接降低藥劑對人體產生之副作用。當然藥液也可以是口服藥溶於水後之混合液。因此，本發明藉由具有氫氧與霧化藥液之吸入式醫藥組成物，供人體吸入後可以達成更好之治療或醫療效果。
相較於習知技術，本發明提供一種用於治療阿茲海默症之吸入式醫藥組成物及其製備方法，本發明吸入式醫藥組成物除了可以藉由氫氣以去除患者體內之惡性自由基，並藉由霧化藥液以增加患者之藥物吸收療效，透過較少霧化藥液劑量即可達成原先一般口服或注射所需要藥劑量之治療效果，因而能使用少量霧化藥液劑量，間接地降低藥劑對人體產生之副作用。
藉由以上較佳具體實施例之詳述，係希望能更加清楚描述本發明之特徵與精神，而並非以上述所揭露的較佳具體實施例來對本發明之範疇加以限制。相反地，其目的是希望能涵蓋各種改變及具相等性的安排於本發明所欲申請之專利範圍的範疇內。因此，本發明所申請之專利範圍的範疇應根據上述的說明作最寬廣的解釋，以致使其涵蓋所有可能的改變以及具相等性的安排。
S1~S3‧‧‧流程步驟

Claims (13)

  1. 一種用於治療阿茲海默症之吸入式醫藥組成物，其特徵包含一第一氣體及一霧化藥液，其中該第一氣體包含一氫氣，該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於4.7%~66.66%之間，該霧化藥液包含選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合。
  2. 如申請專利範圍第1項所述之用於治療阿茲海默症之吸入式醫藥組成物，其中該第一氣體更包含一氧氣。
  3. 如申請專利範圍第2項所述之用於治療阿茲海默症之吸入式醫藥組成物，其中該第一氣體係藉由電解水所產生之一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。
  4. 如申請專利範圍第2項所述之用於治療阿茲海默症之吸入式醫藥組成物，另包含一第二氣體，用以降低該吸入式醫藥組成物中該氫氣之氣體體積濃度，其中該第二氣體係為選自於由空氣、水蒸汽、鈍氣、氧氣及其組合所組成族群中的一種氣體。
  5. 如申請專利範圍第1項所述之用於治療阿茲海默症之吸入式醫藥組成物，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。
  6. 如申請專利範圍第1項所述之用於治療阿茲海默症之吸入式醫藥組成物，其中該霧化藥液係藉由針對一藥液進行霧化或揮發所產生。
  7. 一種用於治療阿茲海默症之吸入式醫藥組成物之製備方法，包含下列步驟： (S1)備製一第一氣體，該第一氣體包含一氫氣；(S2)霧化一藥液以產生一霧化藥液，該藥液包含選自於重酒石酸卡巴拉汀(Rivastigmine Hydrogen Tartrate)、多奈哌齊鹽酸鹽(Donepezil Hydrochloride)、氫溴酸加蘭他敏(Galantamine Hydrobromide)以及美金剛胺鹽酸鹽(Memantine Hydrochloride)所組成族群中之一或其組合；以及(S3)混合該第一氣體以及該霧化藥液以產生該吸入式醫藥組成物，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於4.7%~66.66%之間。
  8. 如申請專利範圍第7項所述之用於治療阿茲海默症之吸入式醫藥組成物之製備方法，於步驟(S2)之後另包含下列步驟：準備一第二氣體。
  9. 如申請專利範圍第8項所述之用於治療阿茲海默症之吸入式醫藥組成物之製備方法，其中該步驟(S3)係為混合該第一氣體、該第二氣體以及該霧化藥液以產生該吸入式醫藥組成物。
  10. 如申請專利範圍第7項所述之用於治療阿茲海默症之吸入式醫藥組成物之製備方法，其中步驟(S1)係為電解水以產生該第一氣體，該第一氣體含一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。
  11. 如申請專利範圍第8項所述之用於治療阿茲海默症之吸入式醫藥組成物之製備方法，其中該第二氣體用以降低該吸入式醫藥組成物中該氫氣之氣體體積濃度。
  12. 如申請專利範圍第8項所述之用於治療阿茲海默症之吸入式醫藥組成物之製備方法，其中該第二氣體係為選自於由空氣、水蒸汽、鈍氣、氧 氣及其組合所組成族群中的一種氣體。
  13. 如申請專利範圍第7項所述之用於治療阿茲海默症之吸入式醫藥組成物之製備方法，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。
TW103110986A 2014-03-25 2014-03-25 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法 TWI602585B (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
TW103110986A TWI602585B (zh) 2014-03-25 2014-03-25 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法
CN201410400001.5A CN104940209A (zh) 2014-03-25 2014-08-14 一种用于治疗阿兹海默症的吸入式药物组合物及其制备方法
US14/664,483 US9463157B2 (en) 2014-03-25 2015-03-20 Inhalation-type pharmaceutical composition for the treatment of Alzheimer's disease and preparation method thereof
JP2015060832A JP2015183005A (ja) 2014-03-25 2015-03-24 アルツハイマー病を治療するための吸入式医薬組成物及びその調製法
DE102015104362.9A DE102015104362A1 (de) 2014-03-25 2015-03-24 Pharmazeutische zusammensetzung vom inhalationstyp für die behandlung der alzheimer-krankheit und zubereitungsverfahren dafür
KR1020150041674A KR20150111327A (ko) 2014-03-25 2015-03-25 흡입형 알츠하이머병 치료용 약제 조성물 및 이의 제조 방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW103110986A TWI602585B (zh) 2014-03-25 2014-03-25 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法

Publications (2)

Publication Number Publication Date
TW201536360A TW201536360A (zh) 2015-10-01
TWI602585B true TWI602585B (zh) 2017-10-21

Family

ID=54146548

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103110986A TWI602585B (zh) 2014-03-25 2014-03-25 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法

Country Status (6)

Country Link
US (1) US9463157B2 (zh)
JP (1) JP2015183005A (zh)
KR (1) KR20150111327A (zh)
CN (1) CN104940209A (zh)
DE (1) DE102015104362A1 (zh)
TW (1) TWI602585B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI586383B (zh) * 2014-04-18 2017-06-11 林信湧 一種用於治療關節炎之吸入式醫藥組成物及其備製方法
JP6395774B2 (ja) * 2016-08-24 2018-09-26 ＭｉＺ株式会社 水素ガスからなる認識機能低下抑制剤
CN107549941A (zh) * 2017-10-13 2018-01-09 钟云山 一种可预防阿兹海默症的项链
JPWO2019082428A1 (ja) * 2017-10-27 2020-11-05 株式会社マイトス 認知症の予防及び／又は治療剤
WO2019163073A1 (ja) * 2018-02-23 2019-08-29 ＭｉＺ株式会社 認知障害または認知症の治療及び／又は予防のための組成物
JP6762620B2 (ja) * 2018-07-06 2020-09-30 ＭｉＺ株式会社 水素ガスからなる認識機能低下抑制剤
JP2020033304A (ja) * 2018-08-30 2020-03-05 医療法人ふじいやさか 薬剤又はサプリメント、組成物、及び水素供給器の使用
JP2021151980A (ja) * 2020-03-24 2021-09-30 ＭｉＺ株式会社 脳炎および／または髄膜炎と当該脳炎および／または髄膜炎に関連する症状を予防および／または改善するための分子状水素含有組成物
KR102601179B1 (ko) * 2022-04-14 2023-11-13 유한책임회사 매드제너레이터 Xr 컨텐츠를 생성하기 위한 장치, 방법 및 시스템

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2526925A1 (en) * 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi A dose adjustable oral pump spray or aerosol spray containing memantine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19734279A1 (de) * 1997-08-07 1999-02-11 Messer Griesheim Gmbh Wasserstoffhaltiges Medikament
FR2812545B1 (fr) 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
DK1874282T3 (da) 2005-04-06 2010-10-25 Adamas Pharmaceuticals Inc Fremgangsmåder og præparater til behandling af CNS lidelser
US20090035383A1 (en) * 2005-08-19 2009-02-05 Shigeo Ohta Scavenger of in vivo harmful reactive oxygen species and/or free radicals
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
CN104379812B (zh) * 2012-06-04 2016-12-14 水株式会社 生物体用高浓度氢气供给装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2526925A1 (en) * 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi A dose adjustable oral pump spray or aerosol spray containing memantine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Drug Discov Ther 2008; 2(5): 264-276 中國中西醫結合外科雜誌 2012年2月第18卷第1期, 102-104頁 *

Also Published As

Publication number Publication date
JP2015183005A (ja) 2015-10-22
US9463157B2 (en) 2016-10-11
DE102015104362A1 (de) 2015-10-08
CN104940209A (zh) 2015-09-30
US20150272867A1 (en) 2015-10-01
KR20150111327A (ko) 2015-10-05
TW201536360A (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
TWI602585B (zh) 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法
TWI629071B (zh) 保健氣體產生器
TWI601542B (zh) 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
TWI569816B (zh) 一種用於治療痛風之吸入式醫藥組成物及其備製方法
TWI589308B (zh) 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法
TWI590837B (zh) 一種用於治療心臟病之吸入式醫藥組成物及其備製方法
TWI586383B (zh) 一種用於治療關節炎之吸入式醫藥組成物及其備製方法
TWI594772B (zh) 一種用於治療高血壓之吸入式醫藥組成物及其備製方法
TWI590838B (zh) 一種用於治療糖尿病之吸入式醫藥組成物及其備製方法
TWI586382B (zh) 一種用於治療腎臟病之吸入式醫藥組成物及其備製方法